IBA upregulated the expression levels of PD‐L1 in the anti‐PD‐L1 antibody treatment group (Figure 6E), activated the ROCK1/c‐Myc/PD‐L1 axis, and suppressed the activation of CD8+ cells within the tumor microenvironment (Figure 6F), reversing the improvement of TILs in mouse tumor tissues (Figure 6G). Here, CD8A is linked to neoplasm.